The discovery of new 11β-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening

Journal of Medicinal Chemistry

Volumn 49, Issue 12, 2006, Pages 3454-3466

  Schuster, Daniela ^a   Maurer, Evelyne M ^b   Laggner, Christian ^a   Nashev, Lyubomir G ^b   Wilckens, Thomas ^c   Langer, Thierry ^a   Odermatt, Alex ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF BERN   (Switzerland)

^c BioNetWorks GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; BVT 2773; ENZYME INHIBITOR; GLUCOCORTICOID; HYDROCORTISONE; LIGAND; LITHOCHOLIC ACID; SEX HORMONE; UNCLASSIFIED DRUG; XDS 01039; GLUCOCORTICOID RECEPTOR;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CATALYST; CELL STRAIN 3T3; COMPUTER PROGRAM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG SYNTHESIS; EMBRYO; ENZYME INHIBITION; ENZYME MECHANISM; HORMONE METABOLISM; HUMAN; HUMAN CELL; HYPERTENSION; MODEL; MOUSE; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; OBESITY; PHARMACOPHORE; SODIUM RETENTION; STEROID METABOLISM; VIRTUAL SCREENING; WOUND HEALING; ANIMAL; BINDING SITE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; FACTUAL DATABASE; GENETIC TRANSFECTION; GENETICS; PHYSIOLOGY; PROTEIN CONFORMATION; TRANSACTIVATION; X RAY CRYSTALLOGRAPHY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; LIGANDS; MICE; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, GLUCOCORTICOID; SOFTWARE; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 33745221417     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0600794     Document Type: Article

References (72)

1. Sapolsky, R. M.; Romero, L. M.; Munck, A. U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 2000, 21, 55-89.
2. Charmandari, E.; Kino, T.; Chrousos, G. P. Glucocorticoids and their actions: an introduction. Ann. N. Y. Acad. Sci. 2004, 1024, 1-8.
3. Ishida-Takahashi, R.; Uotani, S.; Abe, T.; Degawa-Yamauchi, M.; Fukushima, T.; et al. Rapid inhibition of leptin signaling by glucocorticoids in vitro and in vivo. J. Biol. Chem. 2004, 279, 19658-19664.
4. Lambillotte, C.; Gilon, P.; Henquin, J. C. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J. Clin. Invest. 1997, 99, 414-423.
5. Dimitriadis, G.; Leighton, B.; Parry-Billings, M.; Sasson, S.; Young, M.; et al. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem. J. 1997, 321 (Part 3), 707-712.
6. Abdallah, B. M.; Beck-Nielsen, H.; Gaster, M. Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur. J. Clin. Invest. 2005, 35, 627-634.
7. Lundgren, M.; Buren, J.; Ruge, T.; Myrnas, T.; Eriksson, J. W. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J. Clin. Endocrinol. Metab. 2004, 89, 2989-2997.
8. Whorwood, C. B.; Donovan, S. J.; Flanagan, D.; Phillips, D. I.; Byrne, C. D. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002, 51, 1066-1075.
9. Odermatt, A. 11beta-hydroxysteroid dehydrogenase type 1: A potential therapeutic target for the control of local glucocorticoid concentrations. Curr. Enzyme Inhib. 2005, 1, 97-105.
10. Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294, 2166-2170.
11. Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 2003, 112, 83-90.
12. Paterson, J. M.; Morton, N. M.; Fievet, C.; Kenyon, C. J.; Holmes, M. C.; et al. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 7088-7093.
13. Kotelevtsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmoll, D.; et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14924-14929.
14. Lindsay, R. S.; Wake, D. J.; Nair, S.; Bunt, J.; Livingstone, D. E.; et al. Subcutaneous adipose 11beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 2003, 88, 2738-2744.
15. Valsamakis, G.; Anwar, A.; Tomlinson, J. W.; Shackleton, C. H.; McTernan, P. G.; et al. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2004, 89, 4755-4761.
16. Rask, E.; Walker, B. R.; Soderberg, S.; Livingstone, D. E.; Eliasson, M.; et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: Increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 2002, 87, 3330-3336.
17. Paulmyer-Lacroix, O.; Boullu, S.; Oliver, C.; Alessi, M. C.; Grino, M. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: An in situ hybridization study. J. Clin. Endocrinol. Metab. 2002, 87, 2701-2705.
18. Kannisto, K.; Pietilainen, K. H.; Ehrenborg, E.; Rissanen, A.; Kaprio, J.; et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: Studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab. 2004, 89, 4414-4421.
19. Frey, F. J.; Odermatt, A.; Frey, B. M. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr. Opin. Nephrol. Hypertens. 2004, 13, 451-458.
20. Odermatt, A.; Arnold, P.; Stauffer, A.; Frey, B. M.; Frey, F. J. The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J. Biol. Chem. 1999, 274, 28762-28770.
21. Baker, M. E. Evolutionary analysis of 11beta-hydroxysteroid dehydrogenase-type 1, -type 2, -type 3 and 17beta-hydroxysteroid dehydrogenase-type 2 in fish. FEBS Lett. 2004, 574, 167-170.
22. Hosfield, D. J.; Wu, Y.; Skene, R. J.; Hilgers, M.; Jennings, A.; et al. Conformational flexibility in crystal structures of human 11beta-hydroxysteroid dehydrogenase type 1 provide insights into glucocorticoid interconversion and enzyme regulation. J. Biol. Chem. 2005, 280, 4639-4648.
23. Ogg, D.; Elleby, B.; Norstroem, C.; Stefansson, K.; Abrahmsen, L.; et al. The crystal structure of guinea pig 11b-hydroxysteroid dehydrogenase type 1 provides a model for enzyme-lipid bilayer interactions. J. Biol. Chem. 2005, 280, 3789-3794.
24. Zhang, J.; Osslund, T. D.; Plant, M. H.; Clogston, C. L.; Nybo, R. E.; et al. Crystal structure of murine 11β-hydroxysteroid dehydrogenase 1: An important therapeutic target for diabetes. Biochemistry 2005, 44, 6948-6957.
25. Berman, H. M.; Westbrook, J.; Feng, Z.; Gililand, G.; Bhat, T. N.; et al. The protein data bank. Nucleic Acids Res. 2000, 28, 235-242.
26. Arampatzis, S.; Kadereit, B.; Schuster, D.; Balazs, Z.; Schweizer, R. A.; et al. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J. Mol. Endocrinol. 2005, 35, 89-101.
27. Jorgensen, W. L. The many roles of computation in drug discovery. Science 2004, 303, 1813-1818.
28. Ekins, S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discovery Today 2004, 9, 276-285.
29. Kurogi, Y.; Guner, O. F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
30. Bajorath, J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discovery 2002, 1, 882-894.
31. Shoichet, B. K. Virtual screening of chemical libraries. Nature 2004, 432, 862-865.
32. van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discovery 2003, 2, 192-204.
33. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 22, 3-25.
34. Lipinski, C. A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today 2004, 1, 337-341.
35. Doman, T. N.; McGovern, S. L.; Witherbee, B. J.; Kasten, T. P.; Kurumbail, R.; et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 2002, 45, 2213-2221.
36. Barf, T.; Vallgarda, J.; Emond, R.; Haggstrom, C.; Kurz, G.; et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2002, 45, 3813-3815.
37. Vicker, N.; Su, X.; Ganeshapillai, D.; Purohit, A.; Reed, M. J.; et al. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2. WO 2004/037251.
38. Morris, D. J.; Souness, G. W.; Latif, S. A.; Hardy, M. P.; Brem, A. S. Effect of chenodeoxycholic acid on 11b-hydroxysteroid dehydrogenase in various target tissues. Metab. Clin. Exp. 2004, 53, 811-816.
39. Stauffer, A. T.; Rochat, M. K.; Dick, B.; Frey, F. J.; Odermatt, A. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J. Biol. Chem. 2002, 277, 26286-26292.
40. Derwent World Drug Index, 2003 ed.; Derwent Publications Ltd.: London, 2003.
41. Vicker, N.; Su, X.; Lawrence, H.; Cruttenden, A.; Purohit, A.; et al. A novel 18beta-glycyrrhetinic acid analogue as a potent and selective inhibitor of 11beta-hydroxysteroid dehydrogenase 2. Bioorg. Med. Chem. Lett. 2004, 14, 3263-3267.
42. Schuster, D.; Laggner, C.; Steindl, T. M.; Palusczak, A.; Hartmann, R. W.; Langer, T. Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. J. Comput. Inf. Model. 2006, ASAP Article: DOI: 10.1021/ci050237k.
43. Niederreiter, D. Why Drugs Fail-A Study on Side Effects in New Chemical Entities; Department of Pharmaceutical Chemistry, University of Innsbruck: Innsbruck, 2004.
44. Atanasov, A. G.; Nashev, L. G.; Schweizer, R. A.; Frick, C.; Odermatt, A. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett. 2004, 571, 129-133.
45. Lavery, G. G.; Walker, E. A.; Draper, N.; Jeyasuria, P.; Marcos, J.; et al. Hexose-6-phosphate dehydrogenase knockout mice lack 11beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J. Biol. Chem. 2006, 281, 6546-6551.
46. Hasselgren, P. O. Glucocorticoids and muscle catabolism. Curr. Opin. Clin. Nutr. Metab. Care 1999, 2, 201-205.
47. Schweizer, R. A.; Atanasov, A. G.; Frey, B. M.; Odermatt, A. A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): Flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol. Cell. Endocrinol. 2003, 212, 41-49.
48. Sandeep, T. C.; Yau, J. L.; MacLullich, A. M.; Noble, J.; Deary, I. J.; et al. 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6734-6739.
49. Small, G. R.; Hadoke, P. W.; Sharif, I.; Dover, A. R.; Armour, D.; et al. Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 12165-12170.
50. Alberts, P.; Nilsson, C.; Selen, G.; Engblom, L. O.; Edling, N. H.; et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003, 144, 4755-4762.
51. Alberts, P.; Engblom, L.; Edling, N.; Forsgren, M.; Klingstrom, G.; et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45, 1528-1532.
52. Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 2005, 202, 517-527.
53. Coppola, G. M.; Kukkola, P. J.; Stanton, J. L.; Neubert, A. D.; Marcopulos, N.; et al. Perhydroquinolylbenzamides as novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2005, 48, 6696-6712.
54. Fotsch, C.; Askew, B. C.; Chen, J. J. 11beta-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases. Expert Opin. Ther. Pat. 2005, 15, 289-303.
55. Su, X.; Lawrence, H.; Ganeshapillai, D.; Cruttenden, A.; Purohit, A.; et al. Novel 18beta-glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenases. Bioorg. Med. Chem. 2004, 12, 4439-4457.
56. Odermatt, A.; Atanasov, A. G.; Balazs, Z.; Schweizer, R. A.; Nashev, L. G.; et al. Why is 11beta-hydroxysteroid dehydrogenase type 1 facing the endoplasmic reticulum lumen? Physiological relevance of the membrane topology of 11beta-HSD1. Mol. Cell. Endocrinol. 2006, 248, 15-30.
57. Koch, M. A.; Wittenberg, L. O.; Basu, S.; Jeyaraj, D. A.; Gourzoulidou, E.; et al. Compound library development guided by protein structure similarity clustering and natural product structure. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 16721-16726.
58. Koch, M. A.; Schuffenhauer, A.; Scheck, M.; Wetzel, S.; Casaulta, M.; et al. Charting biologically relevant chemical space: a structural classification of natural products (SCONP). Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17272-17277.
59. Bujalska, I. J.; Walker, E. A.; Hewison, M.; Stewart, P. M. A switch in dehydrogenase to reductase activity of 11beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J. Clin. Endocrinol. Metab. 2002, 87, 1205-1210.
60. Langer, T.; Wolber, G. Virtual combinatorial chemistry and in silico screening: Efficient tools for lead structure discovery? Pure Appl. Chem. 2004, 76, 991-996.
61. Recanatini, M.; Bottegoni, G.; Cavalli, A. In silico antitarget screening. Drug Discovery Today 2004, 1, 209-215.
62. Pipeline Pilot, Vers. 5.0.1.100; SciTegic: San Diego, CA, 2005.
63. SciFinder, 2006 ed.; American Chemical Society: Washington, DC, 2006.
64. Reddy, N. L.; Hill, J.; Ye, L.; Fernandes, P. B.; Stout, D. M. Identification and strucutreactivity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis. Bioorg. Med. Chem. 2004, 14, 5645-5649.
65. Natarajan, S. K.; Moreno, O.; Graddis, T. J.; Duncan, D.; Laus, R.; et al. Compositions and methods for the treatment for disease associated with Trp-p8 expression. WO 2005/020897, March 10, 2005.
66. Andersen, H. S.; T., K. G. C.; Christensen, I. T.; Mogensen, J. P.; Larsen, A. R.; et al. Pharmaceutical use of substituted amides. WO 2004/089470, October 21, 2004.
67. Kampen, G. C. T.; Andersen, H. S. Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy. WO 2004/089415, October 21, 2004.
68. Catalyst Software Package, Version 4.9; Accelrys Software Inc.: San Diego, CA, 2003.
69. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. Identification of common functional configurations among molecules. J. Chem. Inf. Comput. Sci. 1996, 36, 536-571.
70. Clement, O. O.; Mehl, A. T. HipHop: Pharmacophores based on multiple common-feature alignments. Pharmacophore Perception, Development, and Use in Drug Design; International University Line: La Jolla, CA, 2000; pp 69-84.
71. Catalyst Software Package, Tutorial Release 4.9; Accelrys Software Inc.: San Diego, CA, 2003.
72. Verdonk, M. L.; Chessari, G.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; et al. Modeling water molecules in protein-ligand docking using GOLD. J. Med. Chem. 2005, 48, 6504-6515.